On July 10, the case of Sexaur et al v. Intellicell Biosciences moves forward with the initial pretrial conference.
As you recall, Sexaur is Intellicell's former vice president of Clinical Research and Development who stated his internal emails were ignored when he warned that several qualified institutions found Intellicell's cell population to be inert or dead. He claimed the data was ignored and the company continued to make claims to investors, to regulators, to patients, to the communities at large that these cell populations are live cells.
Meanwhile, it is now more than 3 months since the annual report was due and more than 6 months since that period ended.
